http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
-
U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine
-
U.S. authorizes third shot of COVID-19 vaccines for the immunocompromised
-
Pfizer (PFE) And BioNTech SE (BNTX) Announces Additional 200M Vaccine Order from US Government
-
Pfizer And BioNTech to Supply U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
-
Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
-
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471
-
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471
-
Pfizer (PFE) Announces FDA Will not Meet PDUFA Goals for Abrocitinib and XELJANZ® Filings
-
Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings
-
BioNTech SE (BNTX) and Pfizer (PFE) Collaborate with SAR's Biovac for Vaccine Distribution in Africa
-
Pfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses within Africa
-
Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa
-
Pfizer Announces New Investor Relations Leader
-
Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate
-
U.S. FDA sets January target to decide on approval of Pfizer's COVID-19 shot
-
Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease
-
Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease
-
Transgene: First Patient Enrolled in Expanded Phase II Clinical Trial of TG4001 + Avelumab Vs Avelumab Alone in Patients With HPV16-positive Anogenital Cancers
-
Pfizer Declares Third-Quarter 2021 Dividend
-
First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
-
Pfizer (PFE) Announces Data Published in NEJM Shows its Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia
-
Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer July 28 Conference Call with Analysts
-
Pfizer (PFE), BioNTech (BNTX) to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations
-
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations
-
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations
-
U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older
-
Pfizer (PFE), BioNTech (BNTX) Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents
-
Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents
-
Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
-
Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
-
Pfizer (PFE) Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech (BNTX) COVID-19 Vaccine in Older Adults
-
Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults
-
Pfizer (PFE), BioNTech SE (BNTX) to Supply EU with 1.8 Billion Additional Doses of COVID-19 Vaccine
-
Pfizer (PFE), BioNTech (BNTX) Sign Agreement for Additional Supply to Turkey of 60 Million Doses of their COVID-19 Vaccine
-
Pfizer and BioNTech Sign Agreement for Additional Supply to Turkey of 60 Million Doses of their COVID-19 Vaccine
-
Pfizer and BioNTech to Supply the European Union with up to 1.8 Billion Additional Doses of COMIRNATY®
-
Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY®
-
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
-
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
-
Pfizer (PFE) and BioNTech (BNTX) Initiate Rolling Submission of BLA for U.S. FDA Approval of Their COVID-19 Vaccine
-
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of their COVID-19 Vaccine
-
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID-19 Vaccine
-
Pfizer (PFE) and BioNTech (BNTX) to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games
-
Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games
-
Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games
-
Pfizer (PFE), BioNTech (BNTX) Submit Request to Expand Conditional Marketing Authorization of Vaccine in EU to Adolescents
-
Pfizer and BioNTech Submit Request to Expand Conditional Marketing Authorization of COMIRNATY® in the EU to Adolescents
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

